Literature DB >> 11461919

Alternative splicing determines the function of CYP4F3 by switching substrate specificity.

P Christmas1, J P Jones, C J Patten, D A Rock, Y Zheng, S M Cheng, B M Weber, N Carlesso, D T Scadden, A E Rettie, R J Soberman.   

Abstract

Diversity of cytochrome P450 function is determined by the expression of multiple genes, many of which have a high degree of identity. We report that the use of alternate exons, each coding for 48 amino acids, generates isoforms of human CYP4F3 that differ in substrate specificity, tissue distribution, and biological function. Both isoforms contain a total of 520 amino acids. CYP4F3A, which incorporates exon 4, inactivates LTB4 by omega-hydroxylation (Km = 0.68 microm) but has low activity for arachidonic acid (Km = 185 microm); it is the only CYP4F isoform expressed in myeloid cells in peripheral blood and bone marrow. CYP4F3B incorporates exon 3 and is selectively expressed in liver and kidney; it is also the predominant CYP4F isoform in trachea and tissues of the gastrointestinal tract. CYP4F3B has a 30-fold higher Km for LTB4 compared with CYP4F3A, but it utilizes arachidonic acid as a substrate for omega-hydroxylation (Km = 22 microm) and generates 20-HETE, an activator of protein kinase C and Ca2+/calmodulin-dependent kinase II. Homology modeling demonstrates that the alternative exon has a position in the molecule which could enable it to contribute to substrate interactions. The results establish that tissue-specific alternative splicing of pre-mRNA can be used as a mechanism for changing substrate specificity and increasing the functional diversity of cytochrome P450 genes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11461919     DOI: 10.1074/jbc.M104818200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Disruption of mouse cytochrome p450 4f14 (Cyp4f14 gene) causes severe perturbations in vitamin E metabolism.

Authors:  Sabrina A Bardowell; Faping Duan; Danny Manor; Joy E Swanson; Robert S Parker
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

2.  CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime].

Authors:  Michael Zhuo Wang; Janelle Y Saulter; Etsuko Usuki; Yen-Ling Cheung; Michael Hall; Arlene S Bridges; Greg Loewen; Oliver T Parkinson; Chad E Stephens; James L Allen; Darryl C Zeldin; David W Boykin; Richard R Tidwell; Andrew Parkinson; Mary F Paine; James Edwin Hall
Journal:  Drug Metab Dispos       Date:  2006-09-22       Impact factor: 3.922

Review 3.  A genomic overview of pyridoxal-phosphate-dependent enzymes.

Authors:  Riccardo Percudani; Alessio Peracchi
Journal:  EMBO Rep       Date:  2003-09       Impact factor: 8.807

4.  Altered leukotriene B4 metabolism in CYP4F18-deficient mice does not impact inflammation following renal ischemia.

Authors:  Valeria Winslow; Rachel Vaivoda; Aleksandr Vasilyev; David Dombkowski; Karim Douaidy; Christopher Stark; Justin Drake; Evin Guilliams; Dharamainder Choudhary; Frederic Preffer; Ivaylo Stoilov; Peter Christmas
Journal:  Biochim Biophys Acta       Date:  2014-03-14

Review 5.  Vascular actions of 20-HETE.

Authors:  Samantha L Hoopes; Victor Garcia; Matthew L Edin; Michal L Schwartzman; Darryl C Zeldin
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-03-23       Impact factor: 3.072

6.  Common variants of cytochrome P450 4F2 exhibit altered vitamin E-{omega}-hydroxylase specific activity.

Authors:  Sabrina A Bardowell; David E Stec; Robert S Parker
Journal:  J Nutr       Date:  2010-09-22       Impact factor: 4.798

7.  The revised human liver cytochrome P450 "Pie": absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics.

Authors:  Scott Michaels; Michael Zhuo Wang
Journal:  Drug Metab Dispos       Date:  2014-05-09       Impact factor: 3.922

8.  Expression of CYP4F2 in human liver and kidney: assessment using targeted peptide antibodies.

Authors:  Vandana Hirani; Anton Yarovoy; Anita Kozeska; Ronald P Magnusson; Jerome M Lasker
Journal:  Arch Biochem Biophys       Date:  2008-07-16       Impact factor: 4.013

9.  PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease.

Authors:  James P Hardwick; Douglas Osei-Hyiaman; Homer Wiland; Mohamed A Abdelmegeed; Byoung-Joon Song
Journal:  PPAR Res       Date:  2010-03-16       Impact factor: 4.964

Review 10.  CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities.

Authors:  Katheryne Z Edson; Allan E Rettie
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.